Andrew Boyer - Amneal Pharmaceuticals, President
| AMRX Stock | USD 7.82 0.10 1.26% |
President
Mr. Andrew S. Boyer is Executive Vice President Commercial Operations of the Company. Prior to joining Amneal, Mr. Boyer served as President CEO of North America Generics, Teva Pharmaceutical Industries Ltd. from August 2016 to February 2018. Before that, Mr. Boyer was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan from September 2006 to August 2016. Mr. Boyer joined Allergan in 1998 as Associate Director of Marketing in Generics. Before joining Allergan, Mr. Boyer served as National Accounts Manager for LederleAmerican Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines since 2020.
| Age | 58 |
| Tenure | 4 years |
| Address | 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807 |
| Phone | 908 947 3120 |
| Web | https://amneal.com |
Andrew Boyer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Boyer against Amneal Pharmaceuticals, stock is an integral part of due diligence when investing in Amneal Pharmaceuticals,. Andrew Boyer insider activity provides valuable insight into whether Amneal Pharmaceuticals, is net buyers or sellers over its current business cycle. Note, Amneal Pharmaceuticals, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amneal Pharmaceuticals,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Boyer over three months ago Disposition of 40225 shares by Andrew Boyer of Amneal Pharmaceuticals, at 7.85 subject to Rule 16b-3 |
Amneal Pharmaceuticals, Management Efficiency
The company has return on total asset (ROA) of 0.0594 % which means that it generated a profit of $0.0594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8577) %, meaning that it created substantial loss on money invested by shareholders. Amneal Pharmaceuticals,'s management efficiency ratios could be used to measure how well Amneal Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.12 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.04). At this time, Amneal Pharmaceuticals,'s Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 933.3 M in 2024, whereas Total Assets are likely to drop slightly above 3.2 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Juan Sanchez | Intracellular Th | 53 | |
| Michael Olchaskey | Intracellular Th | N/A | |
| Luis Aragon | Procaps Group SA | 60 | |
| Stephen Carey | ANI Pharmaceuticals | 53 | |
| Mark Neumann | Intracellular Th | 61 | |
| Rob Aukerman | Phibro Animal Health | 66 | |
| Robert Davis | Intracellular Th | 73 | |
| David Gaffin | Alkermes Plc | 52 | |
| Thomas Dagger | Phibro Animal Health | 66 | |
| Ryan Spencer | Dynavax Technologies | 46 | |
| Samson Li | Phibro Animal Health | 52 | |
| John Bardi | Intracellular Th | N/A | |
| Kurt Knab | Evolus Inc | N/A | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
| Daniel Bendheim | Phibro Animal Health | 52 | |
| Marcela Pagano | Procaps Group SA | 57 | |
| Ramon Fuenmayor | Phibro Animal Health | N/A | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Crystal Muilenburg | Evolus Inc | 44 | |
| Michael Ostrach | Dynavax Technologies | 72 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
Management Performance
| Return On Equity | -1.86 | ||||
| Return On Asset | 0.0594 |
Amneal Pharmaceuticals, Leadership Team
Elected by the shareholders, the Amneal Pharmaceuticals,'s board of directors comprises two types of representatives: Amneal Pharmaceuticals, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amneal. The board's role is to monitor Amneal Pharmaceuticals,'s management team and ensure that shareholders' interests are well served. Amneal Pharmaceuticals,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amneal Pharmaceuticals,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sanjay Jain, President Operations | ||
| Anastasios Konidaris, Chief Financial Officer, Executive Vice President | ||
| John Kiely, Independent Director | ||
| Gautam Patel, Director | ||
| Pranav Mehta, Senior Management | ||
| Nikita Shah, Chief Human Resource Officer, Executive Vice President, Strategic Planning Officer | ||
| Paul Meister, Independent Chairman of the Board | ||
| Jason Esq, Chief VP | ||
| Andrew Boyer, Executive Vice President, Chief Commercial Officer - Generics | ||
| Ted Nark, Independent Director | ||
| Jeffrey George, Independent Director | ||
| Shlomo Yanai, Independent Director | ||
| Nikunj Patel, Head Ltd | ||
| Gregory Sgammato, Senior Development | ||
| Chintu Patel, Co-Chief Executive Officer, Co-Founder, Director | ||
| Stephen Manzano, Senior Vice President, General Counsel and Corporate Secretary | ||
| Sanjiv Patel, VP Operations | ||
| Emily Alva, Independent Director | ||
| Anthony DiMeo, Director Relations | ||
| Joseph Greer, Senior Vice President - Global Quality Management | ||
| Jason Daly, Senior Vice President Chief Legal Officer and Corporate Secretary | ||
| Apurva Saraf, Senior Vice President - Corporate Development | ||
| Chintu RPh, CoCEO CoFounder | ||
| RPh RPh, CoCEO CoFounder | ||
| J Buchi, Independent Director | ||
| Chirag Patel, President, Co-Chief Executive Officer, Co-Founder, Director | ||
| Joseph Todisco, Executive Vice President, Chief Commercial Officer - Specialty |
Amneal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amneal Pharmaceuticals, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.86 | ||||
| Return On Asset | 0.0594 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 5.08 B | ||||
| Shares Outstanding | 309.84 M | ||||
| Shares Owned By Insiders | 52.19 % | ||||
| Shares Owned By Institutions | 46.48 % | ||||
| Number Of Shares Shorted | 4.67 M | ||||
| Price To Earning | 230.50 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.